Archives

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
How This Education Play Has Defied The Weak Stock Market And Soared To All-Time Highs
Market Updates

How This Education Play Has Defied The Weak Stock Market And Soared To All-Time Highs

Adtalem Global stock is hitting all-time highs in the current stock market with its focus on health care education services. Continue Reading View Comments

  • May 09, 2025 05:00 AM PDT
  • EODHD
There's Plenty To Like About The Latest Follow-Through Day
Market Updates

There's Plenty To Like About The Latest Follow-Through Day

There's plenty to like about the latest stock market rally after follow-through days for the Nasdaq and S&P 500 on April 22. Continue Reading View Comments

  • May 09, 2025 05:00 AM PDT
  • EODHD
Why Asia is quietly turning its back on US dollar
Forex

Why Asia is quietly turning its back on US dollar

Something unusual is happening in global currency markets, and most people aren’t paying attention.  This week, the Taiwan dollar surged more than 5% in a single day, recording its biggest jump since 1988.  At the same time, Asian banks, exporters, and sovereign funds are increasingly trying to bypass the US dollar in their transactions.  It’s […]

  • May 09, 2025 04:48 AM PDT
  • Invezz
How China’s rare earth exports ban will affect global and Germany supply chains?
Commodities

How China’s rare earth exports ban will affect global and Germany supply chains?

China has imposed a ban on the export of seven rare earth elements without an export license, effective since April 4.  This action, based on recent history, suggests potential disruptions to global supply chains due to anticipated delays in the issuance of these necessary licenses, Commerzbank AG said in a report. Germany sources a significant […]

  • May 09, 2025 04:42 AM PDT
  • Invezz
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
Market Updates

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabol...

  • May 09, 2025 04:41 AM PDT
  • EODHD
British Airways parent inks $13bn Boeing deal after US-UK trade breakthrough: why it matters
Economy

British Airways parent inks $13bn Boeing deal after US-UK trade breakthrough: why it matters

International Airlines Group, the owner of British Airways, has placed a landmark order for 32 long-haul jets from Boeing worth nearly $13bn (£9.8bn), a day after a trade agreement between the UK and US led to the scrapping of tariffs on jet engines. The announcement, made on Friday, comes just a day after the United […]

  • May 09, 2025 04:40 AM PDT
  • Invezz
Canadian Utilities Appoints Nancy Southern as Executive Chair and Bob Myles as CEO
Market Updates

Canadian Utilities Appoints Nancy Southern as Executive Chair and Bob Myles as CEO

Canadian Utilities (CU.TO) on Thursday appointed Nancy Southern as executive chair and Bob Myles as PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscriptio...

  • May 09, 2025 04:38 AM PDT
  • EODHD
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Market Updates

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EA...

  • May 09, 2025 04:11 AM PDT
  • EODHD
Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025
Market Updates

Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025

CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...

  • May 09, 2025 04:00 AM PDT
  • EODHD
Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series
Market Updates

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammator...

  • May 09, 2025 04:00 AM PDT
  • EODHD